[en] Pulmonary vascular diseases such as pulmonary embolism and pulmonary hypertension are important and frequently under-recognised conditions. This article provides an overview of key highlights in pulmonary vascular diseases from the European Respiratory Society International Congress 2023. This includes insights into disease modification in pulmonary arterial hypertension and novel therapies such as sotatercept and seralutinib. Exciting developments in our understanding of the mechanisms underpinning pulmonary hypertension associated with interstitial lung disease are also explored. A comprehensive overview of the complex relationship between acute pulmonary embolism and chronic thromboembolic pulmonary hypertension (CTEPH) is provided along with our current understanding of the molecular determinants of CTEPH. The importance of multidisciplinary and holistic care cannot be understated, and this article also addresses advances beyond medication, with a special focus on exercise training and rehabilitation.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Cullivan, Sarah ; The National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland
Boucly, Athénaïs ; National Heart and Lung Institute, Imperial College London, London, UK ; Institut National de la Santé et de la Recherche Scientifique, Unité Mixte de Recherche S_999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France ; Assistance Publique - Hôpitaux de Paris, Groupe Hospitalo-Universitaire Paris-Saclay, Hôpital Bicêtre, Service de Pneumologie et Soins Intensifs, Centre de Référence de l'Hypertension Pulmonaire PulmoTension, Le Kremlin-Bicêtre, France
Jevnikar, Mitja; Institut National de la Santé et de la Recherche Scientifique, Unité Mixte de Recherche S_999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France ; Assistance Publique - Hôpitaux de Paris, Groupe Hospitalo-Universitaire Paris-Saclay, Hôpital Bicêtre, Service de Pneumologie et Soins Intensifs, Centre de Référence de l'Hypertension Pulmonaire PulmoTension, Le Kremlin-Bicêtre, France
Lechartier, Benoit; Service de Pneumologie, Département de Médecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Ulrich, Silvia ; Clinic of Pulmonology, Pulmonary Hypertension Unit, University Hospital Zurich, Zurich, Switzerland
Bertoletti, Laurent ; Département of Médecine Vasculaire et Thérapeutique, Université Jean Monnet Saint-Étienne, CHU Saint-Étienne, Mines Saint-Étienne, INSERM, SAINBIOSE U1059, CIC 1408, Saint-Étienne, France
Sitbon, Olivier ; Institut National de la Santé et de la Recherche Scientifique, Unité Mixte de Recherche S_999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France ; Assistance Publique - Hôpitaux de Paris, Groupe Hospitalo-Universitaire Paris-Saclay, Hôpital Bicêtre, Service de Pneumologie et Soins Intensifs, Centre de Référence de l'Hypertension Pulmonaire PulmoTension, Le Kremlin-Bicêtre, France
Vonk-Noordegraaf, Anton ; Department of Pulmonary Medicine, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Bokan, Aleksandar; SLK Clinics, Department of Pneumonology and Intensive Care Medicine, Loewenstein, Germany
Park, Da-Hee; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany
Genecand, Leon ; Division of Pulmonary Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland
Guiot, Julien ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Jutant, Etienne-Marie ; Respiratory Department, CHU de Poitiers, INSERM CIC 1402, IS-ALIVE Research Group, University of Poitiers, Poitiers, France
Piccari, Lucilla ; Department of Pulmonary Medicine, Hospital del Mar, Barcelona, Spain
Lichtblau, Mona ; Clinic of Pulmonology, Pulmonary Hypertension Unit, University Hospital Zurich, Zurich, Switzerland
Ramjug S, Weatherald J, Sahay S, et al. ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Res 2020; 6: 00304-2020.
Lichtblau M, Piccari L, Ramjug S, et al. ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Res 2022; 8: 00665-2021.
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61: 2200879.
Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 2021; 384: 1204–1215.
Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023; 388: 1478–1490.
Souza R, Badesch DB, Ghofrani HA, et al. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J 2023; 62: 2301107.
Frantz RP, Benza RL, Channick RN, et al. TORREY, a phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulm Circ 2021; 11: 20458940211057071.
Zamanian R, Rahaghi FN, Howard LS, et al. Seralutinib improves pulmonary arterial blood vessel volume distribution in pulmonary arterial hypertension (PAH): results of the TORREY phase 2 imaging substudy. Eur Respir J 2023; 62: Suppl. 67, OA742.
Grobs Y, Romanet C, Bourgeois A, et al. Targeting ATP citrate kyase to mitigate vascular remodeling pathogenesis. Eur Respir J 2023; 62: Suppl. 67, PA441.
Kurakula KB, Sun X-Q, Bonnet S, et al. Selective inhibition of histone deacetylases reverses vascular remodeling and improves right ventricle function in pulmonary hypertension. Eur Respir J 2023; 62: Suppl. 67, PA445.
Mirza S, Dunmore B, Morrell N. The role of BMP9-induced Sema3G in pulmonary vascular stability. Eur Respir J 2023; 62: Suppl. 67, PA446.
Lemay S-E, Grobs Y, Martineau S, et al. Targeting DHPS-mediated hypusination of eIF5A improves vascular remodeling in PAH. Eur Respir J 2023; 62: Suppl. 67, PA449.
Lemay S-E, Montesinos MS, Grobs Y, et al. The fibronectin-binding integrins system as a contributor to PAH pathogenesis. Eur Respir J 2023; 62: Suppl. 67, PA453.
Mumby S, Wort S, Perros F, et al. Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1. Eur Respir J 2023; 62: Suppl. 67, PA452.
Bourgeois A, Lemay S-E, Grobs Y, et al. Role of histone acetyltransferases P300/CBP in pulmonary arterial hypertension and right heart failure. EurRespirJ2023; 62: Suppl. 67, PA458.
Schang G, Poujol De Molliens M, Brûlé E, et al. HS135, a novel activin and GDF trap, is highly efficacious in models of group 1 and group 2 pulmonary hypertension (PH). Eur Respir J 2023; 62: Suppl. 67, PA450.
Duijvelaar E, Yoshida K, Sun X-Q, et al. Empagliflozin improves mitochondrial biogenesis and ameliorates vascular remodeling in experimental pulmonary arterial hypertension. Eur Respir J 2023; 62: Suppl. 67, PA451.
Mamazhakypov A, Weissmann N, Ghofrani A, et al. Osteopontin in experimental right ventricular remodeling. Eur Respir J 2023; 62: Suppl. 67, PA448.
Galiè N, McLaughlin VV, Rubin LJ, et al. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 2019; 53: 1802148.
Lichtblau M, Titz A, Bahrampoori B, et al. What changed after the 2022 guidelines for pulmonary hypertension? Eur J Intern Med 2023; 118: 1–5.
Cullivan S, Gaine S, Sitbon O. New trends in pulmonary hypertension. Eur Respir Rev 2023; 32: 220211.
Boucly A, Savale L, Montani D, et al. Initial dual oral combination therapy in patient with pulmonary arterial hypertension and cardiovascular comorbidities. Eur Respir J 2023; 62: Suppl. 67, PA1202.
Argula R, Shapiro S, El-Kersh K, et al. The impact of comorbidities on inhaled treprostinil treatment in patients with pulmonary arterial hypertension. Eur Respir J 2023; 62: Suppl. 67, PA1203.
Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021; 384: 325–334.
Ruffenach G, Hong J, Vaillancourt M, et al. Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. Respir Res 2020; 21: 303.
Piccari L, Allwood B, Antoniou K, et al. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: a consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension. Pulm Circ 2023; 13: e12213.
Parikh R, Konstantinidis I, O’Sullivan DM, et al. Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection. Pulm Circ 2022; 12: e12141.
Behr J, Nathan SD. Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. Curr Opin Pulm Med 2021; 27: 396–404.
Rahaghi FF, Kolaitis NA, Adegunsoye A, et al. Screening strategies for pulmonary hypertension in patients with interstitial lung disease: a multidisciplinary Delphi study. Chest 2022; 162: 145–155.
Dwivedi K, Sharkey M, Delany L, et al. Artificial intelligence and computed tomography to improve quantification and prognostication of lung disease in precapillary pulmonary hypertension. Eur Respir J 2023; 62: Suppl. 67, PA3490.
Garcia AR, Torrubiano IV, Blanco L, et al. Reduced pulmonary vascular density in severe pulmonary hypertension associated with chronic lung disease. Eur Respir J 2023; 62: Suppl. 67, PA3491.
Blanco I, Castro RT, Piccari L, et al. Effect of targeted pulmonary arterial hypertension therapy on arterial oxygenation in patients with pulmonary hypertension associated with lung disease: a systematic review and meta-analysis. Eur Respir J 2023; 62: Suppl. 67, PA3500.
Howard L, Stefano S, Meloni F, et al. PH-ILD management and unmet need in Europe: a clinician survey. Eur Respir J 2023; 62: Suppl. 67, PA3486.
Zisman D, Dubrock H, King C, et al. Safety and tolerability of inhaled treprostinil with phosphodiesterase-5 inhibitors in patients with pulmonary hypertension due to interstitial lung disease. Eur Respir J 2023; 62: Suppl. 67, PA3489.
Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms. JAMA 2021; 325: 59–68.
Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism. JAMA 2014; 311: 1117.
van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet 2017; 390: 289–297.
Kearon C, de Wit K, Parpia S, et al. Diagnosis of pulmonary embolism with D-dimer adjusted to clinical probability. N Engl J Med 2019; 381: 2125–2134.
Roy P-M, Friou E, Germeau B, et al. Derivation and validation of a 4-level clinical pretest probability score for suspected pulmonary embolism to safely decrease imaging testing. JAMA Cardiol 2021; 6: 669–677.
Rambaud G, Mai V, Motreff C, et al. Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: post hoc analysis of the PEP trial. Thromb Res 2023; 231: 58–64.
Roy PM, Penaloza A, Hugli O, et al. Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. Eur Heart J 2021; 42: 3146–3157.
Chaibi S, Roy P-M, Arnoux A, et al. Outpatient management of cancer-related pulmonary embolism: a post hoc analysis of the HOME-PE trial. Eur Respir J 2023; 62: Suppl. 67, OA4829.
Castan M, Janisset L, Castan M, et al. Evolution of cardiac biomarkers and short-term prognosis in pulmonary embolism. Eur Respir J 2023; 62: Suppl. 67, OA4828.
Klok FA, van der Hulle T, den Exter PL, et al. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev 2014; 28: 221–226.
Luijten D, Talerico R, Barco S, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: an updated systematic review and meta-analysis. Eur Respir J 2023; 62: 2300449.
Guérin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thromb Haemost 2014; 112: 598–605.
Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57: 2002828.
UZ Leuven. Checklist for CTEPH after acute PE. Date last updated: 27 January 2021. www.uzleuven.be/nl/ centrum-pulmonale-hypertensie/checklist-cteph-after-acute-pe
Candelera RO, Martínez JO, Ceide OT, et al. MicroRNAs as predictors of chronic thromboembolic pulmonary hypertension. Eur Respir J 2023; 62: Suppl. 67, OA4831.
Bochenek ML, Leidinger C, Rosinus NS, et al. Activated endothelial TGF-β1 signaling promotes venous thrombus nonresolution in mice via endothelin-1: potential role for chronic thromboembolic pulmonary hypertension. Circ Res 2020; 126: 162–181.
Manz XD, Szulcek R, Pan X, et al. Epigenetic modification of the von Willebrand factor promoter drives platelet aggregation on the pulmonary endothelium in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2022; 205: 806–818.
Smolders V, Lodder K, Rodríguez C, et al. The inflammatory profile of CTEPH-derived endothelial cells is a possible driver of disease progression. Cells 2021; 10: 737.
Bezzeghoud S, Bouvaist H, Ahmad K, et al. Bleeding under anticoagulant therapy in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: preliminary results from the HEMA-HTP study. Eur Respir J 2023; 62: Suppl. 67, PA5182.
Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 2019; 7: 239–248.
Jansa P, Sadushi-Kolici R, Kopec G, et al. Long-term safety and survival time under subcutaneous treprostinil treatment in patients with severe chronic thromboembolic pulmonary hypertension (CTEPH). Eur Respir J 2023; 62: Suppl. 67, PA5175.
Jaïs X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med 2022; 10: 961–971.
Bunclark K, Liley J, Ruggiero A, et al. An open-source tool for risk prediction in operable CTEPH. Eur Respir J 2023; 62: Suppl. 67, PA5191.
Bunclark K, Fletcher A, Bartnik A, et al. Left ventricular diastolic dysfunction attenuates outcomes in CTEPH. Eur Respir J 2023; 62: Suppl. 67, PA5177.
Fernandes TM, Kim NH, Kerr KM, et al. Distal vessel pulmonary thromboendarterectomy: results from a single institution. J Heart Lung Transplant 2023; 42: 1112–1119.
Simonneau G, Fadel E, Vonk Noordegraaf A, et al. Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021. Eur Respir Rev 2023; 32: 220132.
Wiedenroth CB, Rolf A, Steinhaus K, et al. Riociguat and balloon pulmonary angioplasty improve prognosis in patients with inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2023; 42: 134–139.
Konstantinides SV, Vicaut E, Danays T, et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol 2017; 69: 1536–1544.
Riedel M, Stanek V, Widimsky J, et al. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982; 81: 151–158.
Grünig E, Eichstaedt C, Barberà JA, et al. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. Eur Respir J 2019; 53: 1800332.
Nakazato L, Veronez V, Kiyota T, et al. Perceived barriers to physical activity in pulmonary hypertension. Eur Respir J 2023; 62: Suppl. 67, PA1762.
McCormack C, Kehoe B, Cullivan S, et al. A qualitative exploration of pulmonary hypertension patients’ views and experience with a remotely delivered home-based exercise program. Eur Respir J 2023; 62: Suppl. 67, PA1757.
Vieira E, Rolim JV, Ivanaga I, et al. Inspiratory muscle training in patients with pulmonary hypertension: a double-blind randomized controlled trial. Eur Respir J 2023; 62: Suppl. 67, PA1759.
Newman J, Robertson L, Gobsee J, et al. A pilot study of a digital 1-minute walk test as a novel decentralised endpoint in pulmonary hypertension research. Eur Respir J 2023; 62: Suppl. 67, PA1761.
